Journal of Hematology & Oncology is the official journal of the Chinese American Hematologist and Oncologist Network.
Elotuzumab for the treatment of multiple myeloma
Elotuzumab is one of the first two monoclonal antibodies that gained FDA approval for the treatment of multiple myeloma (MM). It targets SLAMF7, which is highly expressed in normal plasma and MM cells as well ...